NPM1 and acute myeloid leukemia: However, following recommendations from the European Leukaemia Network (Döhner et al., 2010), screening for distinct and recurrent molecular drivers of AML, including Nucleophosmin 1 (NPM1), fms like tyrosine kinase 3 (FLT3), and CCAAT/enhancer-binding protein alpha (CEBPA), are currently being used in routine practice, and have significantly improved individual prognosis and clinical management through more targeted therapeutic approaches (Döhner et al., 2017).